| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | APCS |
| Uniprot No | P02743 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-223aa |
| 氨基酸序列 | HTDLSGKVFVFPRESVTDHVNLITPLEKPLQNFTLCFRAYSDLSRAYSLFSYNTQGRDNELLVYKERVGEYSLYIGRHKVTSKVIEKFPAPVHICVSWESSSGIAEFWINGTPLVKKGLRQGYFVEAQPKIVLGQEQDSYGGKFDRSQSFVGEIGDLYMWDSVLPPENILSAYQGTPLPANILDWQALNYEIRGYVIIKPLVWV |
| 预测分子量 | 27.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于APCS(血清淀粉样蛋白P成分)重组蛋白的模拟参考文献示例(注：部分文献信息为假设性概括，实际文献需通过学术数据库检索确认)：
---
1. **标题**: *"Recombinant expression and functional characterization of human serum amyloid P component (APCS) in Escherichia coli"*
**作者**: Li Y, et al.
**摘要**: 本研究报道了通过大肠杆菌表达系统高效表达重组人源APCS蛋白的优化策略，并验证其与淀粉样纤维的结合活性。通过亲和层析纯化获得高纯度蛋白，圆二色谱分析证实其保留了天然五聚体结构特征。
2. **标题**: *"Structural insights into APCS-mediated amyloid aggregation inhibition"*
**作者**: Smith JR, et al.
**摘要**: 利用X射线晶体学解析了重组APCS蛋白与β-淀粉样肽(Aβ1-42)的复合物结构，揭示了APCS通过特异性结合淀粉样纤维表面抑制病理沉积的分子机制，为淀粉样变性病的治疗提供新靶点。
3. **标题**: *"Role of recombinant APCS in modulating macrophage polarization in Alzheimer's disease models"*
**作者**: Chen X, et al.
**摘要**: 研究证明重组APCS蛋白可通过调节小胶质细胞/巨噬细胞的炎症反应表型，减轻阿尔茨海默病小鼠模型的神经炎症和淀粉样斑块负荷，提示其潜在免疫调节功能。
---
如需真实文献，建议在PubMed或Web of Science中检索关键词：**"recombinant serum amyloid P component"** 或 **"APCS protein expression"**。
**Background of APCS Recombinant Protein**
APCS (Amyloid P Component, Serum) is a conserved glycoprotein belonging to the pentraxin family, characterized by its pentameric structure and calcium-dependent ligand-binding properties. It plays a role in innate immunity, inflammation regulation, and amyloidosis by binding to pathogens, apoptotic cells, and amyloid fibrils. APCS stabilizes amyloid deposits, hindering their clearance and contributing to pathologies like systemic amyloidosis.
Recombinant APCS is produced using genetic engineering, enabling controlled in vitro expression in bacterial (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cells). This method ensures high purity and scalability for research and therapeutic applications. Recombinant APCS retains native structural and functional properties, facilitating studies on its interactions with ligands, immune modulation, and amyloid fibril dynamics.
In research, recombinant APCS aids in elucidating amyloidosis mechanisms, drug screening, and diagnostic assay development. Therapeutically, it is explored for targeting amyloid deposits or modulating immune responses. Challenges include maintaining post-translational modifications critical for functionality, which often requires eukaryotic expression systems.
Overall, recombinant APCS serves as a vital tool for advancing understanding of amyloid-related diseases and developing targeted therapies.
×
